Overview

Clinical Trial to Evaluate the Efficacy and Safety of DP-R212

Status:
Withdrawn
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine superiority of DP-R212 comparing to each monotherapy in patient with hypertension and primary hypercholesterolemia.
Phase:
Phase 3
Details
Lead Sponsor:
Alvogen Korea